Literature DB >> 28926500

Occipital lobe and posterior cingulate perfusion in the prediction of dementia with Lewy body pathology in a clinical sample.

Angus M J Prosser1, Livia Tossici-Bolt, Christopher M Kipps.   

Abstract

OBJECTIVE: The aim of this study was to investigate the diagnostic value of occipital lobe and posterior cingulate perfusion in predicting dopamine transporter imaging outcome using a quantitative measure of analysis. PATIENTS AND METHODS: In total, 99 patients with cognitive complaints who had undergone both technetium-99m-hexamethylpropyleneamine oxime single-photon emission computed tomography (Tc-HMPAO SPECT) and I ioflupane (I-FP-CIT also called DaTSCAN) imaging in a dementia diagnostic center were analyzed. Measures of perfusion were calculated from HMPAO SPECT images for the medial and lateral occipital lobe, the posterior cingulate cortex, precuneus and cuneus regions of interest using statistical parametric mapping 8. DaTSCAN images were quantified and specific binding ratios were calculated independent from HMPAO SPECT results. Statistical parametric mapping and tests of associations between perfusion and I-FP-CIT imaging were completed.
RESULTS: Regions of interest on HMPAO yielded poor predictive values when used independently to predict I-FP-CIT status; however, the combination of normal posterior cingulate perfusion with medial and lateral occipital hypoperfusion was associated significantly with I-FP-CIT status, χ (1, N=99)=9.72, P=0.002. This combination also yielded a high positive likelihood ratio and specificity (11.1, 98%). Sensitivity was, however, low (22%). No significant perfusion differences were found when abnormal and normal I-FP-CIT groups were compared directly using voxel-based morphometry (P<0.05, family-wise error).
CONCLUSION: The combination of medial and lateral occipital hypoperfusion with preserved posterior cingulate gyrus perfusion is highly specific for individuals with a positive I-FP-CIT scan in a clinical sample where diagnostic doubt exists. This regional combination, however, lacks sensitivity; therefore, absence of the sign cannot be used to rule out dementia with Lewy bodies. A positive finding provides strong evidence to rule in dementia with Lewy bodies.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28926500     DOI: 10.1097/MNM.0000000000000750

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  4 in total

1.  Proposing a "Brain Health Checkup (BHC)" as a Global Potential "Standard of Care" to Overcome Reward Dysregulation in Primary Care Medicine: Coupling Genetic Risk Testing and Induction of "Dopamine Homeostasis".

Authors:  Eric R Braverman; Catherine A Dennen; Mark S Gold; Abdalla Bowirrat; Ashim Gupta; David Baron; A Kenison Roy; David E Smith; Jean Lud Cadet; Kenneth Blum
Journal:  Int J Environ Res Public Health       Date:  2022-04-30       Impact factor: 4.614

2.  Occipital and Cingulate Hypometabolism are Significantly Under-Reported on 18-Fluorodeoxyglucose Positron Emission Tomography Scans of Patients with Lewy Body Dementia.

Authors:  Moath Hamed; Frank Schraml; Jeffrey Wilson; James Galvin; Marwan N Sabbagh
Journal:  J Alzheimers Dis Parkinsonism       Date:  2018-02-28

3.  Deep learning identifies brain structures that predict cognition and explain heterogeneity in cognitive aging.

Authors:  Krishnakant V Saboo; Chang Hu; Yogatheesan Varatharajah; Scott A Przybelski; Robert I Reid; Christopher G Schwarz; Jonathan Graff-Radford; David S Knopman; Mary M Machulda; Michelle M Mielke; Ronald C Petersen; Paul M Arnold; Gregory A Worrell; David T Jones; Clifford R Jack; Ravishankar K Iyer; Prashanthi Vemuri
Journal:  Neuroimage       Date:  2022-02-20       Impact factor: 7.400

4.  Global and Regional Changes in Perivascular Space in Idiopathic and Familial Parkinson's Disease.

Authors:  Erin K Donahue; Amjad Murdos; Michael W Jakowec; Nasim Sheikh-Bahaei; Arthur W Toga; Giselle M Petzinger; Farshid Sepehrband
Journal:  Mov Disord       Date:  2021-01-20       Impact factor: 10.338

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.